This website uses cookies

Read our Privacy policy and Terms of use for more information.

Wearables Are Becoming the Front Door to Clinical Care

Wearables are becoming a new front door to clinical care, and both funding and policy trends are moving in that direction.

As you know, I’m a wearable fanatic and have been writing about the clinical implications of this technology for years. I’ve used “Guardian Angel Tech” to describe a future in which wearables continuously monitor you and alert you when something may be wrong.

Recent developments—including Oura’s acquisition of Counsel Health and Withings’ partnership with Dreem Health Sleep Clinic—make this a timely trend to examine.

In this article, I’ll briefly review wearables, explore their emerging role as a front door to clinical care, and discuss the implications for patients, physicians, and the health system.

Wearables 101

Wearables continuously and passively collect data from your body. Smartwatches track heart rate and blood pressure, rings monitor sleep, and patches read glucose in real time.

Rock Health's 2025 consumer adoption survey found that three in five U.S. adults own at least one wearable or connected device, up 33 percentage points since 2015. Eighty-three percent of owners wear it five or more days per week, and 59% have discussed their data with a healthcare provider (I can attest to this as both a patient and physician).

I group the consumer market into three buckets:

Created with Notion AI

  1. Performance Optimization: athletes and health-conscious consumers focused on sleep, recovery, and longevity. WHOOP, Oura, and Garmin target this group.

  2. Lifestyle: average consumers who care about their health but don't need every metric. Step count and resting heart rate are enough.

  3. Detection: consumers and patients who use wearables to watch for abnormal rhythms, falls, or gait changes. This is where Guardian Angel Tech lives. Apple Watch fits here and in the other two buckets.

The line between consumer and medical-grade devices is also blurring, and as physicians we have to care about it. The practical test is whether the FDA has reviewed the device. Apple Watch's hypertension notifications received 510(k) clearance. WHOOP's blood pressure insights did not go through FDA review. A cleared device should get a physician's attention, while data from an uncleared one gets a grain of salt.

Wearables as a Front Door to Clinical Care

Wearables are becoming a front door to clinical care. Imagine a few scenarios:

  • Your Apple Watch detects atrial fibrillation and connects you with a telehealth cardiologist for evaluation.

  • Your WHOOP detects hypertension and connects you with a telehealth primary care provider for further evaluation.

  • Your Eight Sleep mattress identifies a pattern of restless nights and connects you with a sleep medicine doctor.

Some of this already exists, as I’ll show below.

We’ve seen similar front doors emerge in other settings. Retailers like Walmart opened primary care clinics near their stores, hoping to improve access to affordable care in underserved communities and attract shoppers. The retail health trend, however, has struggled.

Digital health companies like Hims & Hers and Ro now serve as front doors for weight management. Patients complete a brief survey and may be connected with GLP-1 treatment. The model has worked well enough that pharmaceutical companies like Lilly and Novo have built their own platforms and partnered with telehealth companies, as well as Oura and Counsel.

I covered how wearable and digital health companies are also offering lab panels. People can get a range of tests. If a result is critical, a clinician will call you. For a routine out-of-range result, you’re mostly pointed back to your own doctor. That makes the handoff the weak spot.

Wearables are following a similar path, with Oura as a prime example:

  • Oura partnered with ResMed. In the U.S., users who receive a nighttime breathing-disturbance notification can access a sleep assessment through the partnership and connect with an independent clinician.

  • Oura acquired Counsel Health to bring clinicians closer to users. Oura members can chat with Counsel’s medical AI and bring a board-certified physician into the conversation. The physician can diagnose, prescribe, or refer when appropriate.

  • Oura’s Medicare Advantage partnership with Essence Healthcare began as a free ring benefit. Essence now uses Oura’s breathing-disturbance data to identify members for sleep apnea outreach. An AI assistant screens them with STOP-BANG, and the results go to their PCP. Oura describes this as a wellness signal, not a diagnosis.

  • Oura is also partnering with MD Live to support members taking GLP-1s. Members can log doses and symptoms alongside their biometrics and share them with their clinician. The service is expected to start in early 2027.

Withings has also partnered with Dreem Health Sleep Clinic to help people understand and treat sleep problems. The service uses up to 14 days of Withings data and an FDA-cleared at-home Sunrise sleep test to create personalized treatment plans, with most insurance plans covering the process.

Funding is moving in the same direction. On November 10, Oura announced an agreement to acquire Counsel Health for $625 million in cash, with closing expected by year-end. Oura has also raised $875 million at an $11 billion valuation, and WHOOP has raised $575 million at a $10.1 billion valuation. Investors are betting that a wearable with a clinician behind it is worth more than a wearable alone.

Policy is moving that way, too. CMS’s ACCESS Model is a newish payment option for technology-supported chronic care in Original Medicare, with full payment tied to outcomes such as blood pressure control. CMS lists Withings, Counsel, and WHOOP-affiliated medical groups as participants, and Counsel’s program with Oura is planned for early 2027.

Dashevsky’s Dissection

I support wearables as a front door to clinical care. The reach of this technology is hard to match, and it can do a lot of good in the world. Whether it does depends on what happens after the alert.

For patients, the biggest benefit will come from Guardian Angel Tech. An algorithm monitors your data in the background, catches subtle changes before they become a problem, and points you toward care. A change in gait could flag an early neurological disorder. A small rise in respiratory rate and heart rate could flag an asthma exacerbation before it happens. Most of these models don’t exist yet and would need FDA review, but you can see where this is going. The Oura sleep apnea examples above are early versions.

The issue is access. Wearable ownership is 67% in households earning over $200K and 41% in households earning under $25K. The patients who would benefit most are the least likely to own the front door.

For physicians, my reservations remain the same. These consumer wearables are not medical grade, so it’s unclear whether their data belongs in the chart. A front door built on that data still has to hand off to a clinician who won’t rely on it and has to start testing and evaluation from scratch. That’s reasonable, and not necessarily a bad thing. The wearable flags something that seems “off,” and the patient moves into a telehealth or in-person visit where guideline-based medicine takes over.

The handoff is what I’d watch, though. Lab panels already show how shaky this can be, since routine out-of-range results mostly send you back to your own doctor. The number I’d ask a wearable company is how many members who start with a wearable alert complete an evaluation, and how often that evaluation changes care.

For health systems, this trend deserves a lot of attention. Wearable companies could become a steady source of referrals, which is another revenue stream. The question is whether this model increases access to care or just funnels patients into health systems. I think it does both. Through telehealth, it increases access. In person, with long wait times, it works as a referral mechanism. For specialty care, where waits are longest, it may be a referral machine and nothing more.

In summary, wearables are becoming a front door to clinical care, and the Oura and Withings partnerships show it’s already happening. The benefit for patients will depend on the handoff that follows the alert, and on whether the people who would gain the most can access it.

Huddle+ Members Only

Want to go deeper? Upgrade to Huddle+

Get exclusive courses, expert analysis, and the tools to understand how healthcare really works—from AI to policy to the business of medicine.

Upgrade Now
Premium courses & guides
Community access
Weekly insights